Indeed, ALL patients categorized into PGR subgroup upregulate BIM expression after 7 days of PRED monotherapy, while in ALL patients belonging to PPR category BIM expression is downregulated or remains unchanged. The gene discussed is BCL2L11; the disease is acute lymphoblastic leukemia.